Ididust

Vaccine approved by Canadian clinical trial, stock price hits record high

In the morning of May 18th, Concino Bio-B (06185.HK) issued an announcement announcing the approval of the clinical trial application for the recombinant coronavirus vaccine (adenovirus vector) (Ad5-nCoV) by Health Canada. As of press time, Kang Xinuo’s share price was 208.6 Hong Kong dollars per share, rising for 9 consecutive trading days, or 138.1%, a record high. This represents a surge of 213.3% from the 97.8 HKD / share that the company announced on March 4 when it was closing the research and development of a new Pneumococcal virus vaccine.Earlier, on April 27, Concino Bio announced that it had submitted a request for a pre-clinical application for a recombinant new coronavirus vaccine (adenovirus vector) clinical trial to Health Canada on April 24, 2020, and Health Canada accepted the request. On May 13th, it was announced that it will cooperate with the National Research Council of Canada to jointly promote the clinical trials of a recombinant new coronavirus vaccine (adenoviral vector) in Canada, starting from clinical phase I / II with the goal of developing clinical phase III.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top
Need Help? Chat with us